Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Synta Pharmaceuticals Corp. Plunged Today

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Synta Pharmaceuticals  (NASDAQ: SNTA  ) sank 16% today after Stifel downgraded the biotechnology company from hold to sell.

So what: Synta surged yesterday after announcing positive news for its lead cancer drug, ganetespib, but today's downgrade by Stifel's Brian Klein is forcing Mr. Market to sober up quickly. So, while investors were quite excited about the fact that ganetespib had been chosen for an investigator-sponsored trial, Klein's call suggests that Synta's fundamentals remain largely unchanged. 

Now what: According to Stifel, Synta's risk/reward trade-off is rather unattractive at this point. "SNTA reported 4Q13 LPS of $(0.31), in line with our $(0.32) estimate," noted Klein. "Due to further delayed data readouts, changes in clinical trial designs, leadership changes, and the further need for capital, we are downgrading Synta (SNTA) to a Sell." Given Synta's worrisome cash-burn rate and still highly speculative pipeline, it's tough to disagree with Stifel's cautious stance. 

More reliable ways to build wealth
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 19, 2014, at 4:43 PM, dphillips76 wrote:

    so basically every bio-pharm as Fundamental issues of one kind or the other. That all gets better once they bring a drup to market. G is fast tracked and now sponsored. Hmmmmmmm

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2873546, ~/Articles/ArticleHandler.aspx, 9/3/2015 6:59:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Pacampara

I take a look at big 10% moves, as well as stock-shaking analyst calls, on a daily basis for The Fool. While I don't believe in active trading, closely monitoring Mr. Market's mood swings can help identify long-term opportunities.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:00 PM
SNTA $2.06 Up +0.08 +4.04%
Synta Pharmaceutic… CAPS Rating: **